RSRenate B. Schnabel

Renate B. Schnabel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Renate B. Schnabel has a total of 191 co-authors. Here are the top co-authors by number of shared publications:

  • Stefan Blankenberg

    Department of General and Interventional Cardiology, University Heart Center Hamburg-Eppendorf, Germany; DZHK (Deutsches Zentrum fuer Herz-Kreislauf-Forschung e.V.), partner site Hamburg/Kiel/Luebeck, Germany

    12 shared publications
  • Karl J. Lackner

    University Medical Center of the Johannes Gutenberg-University Mainz, Germany

    10 shared publications
  • Edith Lubos

    Department of General and Interventional Cardiology, University Heart Center, Hamburg, Germany

    9 shared publications
  • Philipp S. Wild

    9 shared publications
  • Sandra Wilde

    Department of General and Interventional Cardiology, University Heart Center Hamburg-Eppendorf, Germany

    9 shared publications
  • Christoph R. Sinning

    Department of General and Interventional Cardiology, University Heart Center Hamburg-Eppendorf, Germany

    7 shared publications

Latest Publications

  • Cardiovascular Mortality in Chest Pain Patients: Comparison of Natriuretic Peptides With Novel Biomarkers of Cardiovascular Stress

    by Christoph Sinning, Francisco Ojeda, Tanja Zeller, Elvin Zengin, Hans-J. Rupprecht, Karl-J. Lackner, Christoph Bickel, Stefan Blankenberg, Renate B. Schnabel, Dirk Westermann


  • ADMA, subclinical changes and atrial fibrillation in the general population

    by Meike Ramuschkat, Sebastian Appelbaum, Dorothee Atzler, Tanja Zeller, Christoph Bauer, Francisco M. Ojeda, Christoph R. Sinning, Boris Hoffmann, Karl J. Lackner, Rainer H. Böger, et al.


  • Open Access

    Multiple Biomarkers and Atrial Fibrillation in the General Population

    by Renate B. Schnabel, Philipp S. Wild, Sandra Wilde, Francisco M. Ojeda, Andreas Schulz, Tanja Zeller, Christoph R. Sinning, Jan Kunde, Karl J. Lackner, Thomas Munzel, et al.

    Different biological pathways have been related to atrial fibrillation (AF). Novel biomarkers capturing inflammation, oxidative stress, and neurohumoral activation have not been investigated comprehensively in AF. In the population-based Gutenberg Health Study (n = 5000), mean age 56±11 years, 51% males, we measured ten biomarkers representing inflammation (C-reactive protein, fibrinogen), cardiac and vascular function (midregional pro adrenomedullin [MR-proADM], midregional pro atrial natriuretic peptide [MR-proANP], N-terminal pro-B-type natriuretic peptide [Nt-proBNP], sensitive troponin I ultra [TnI ultra], copeptin, and C-terminal pro endothelin-1), and oxidative stress (glutathioneperoxidase-1, myeloperoxidase) in relation to manifest AF (n = 161 cases). Individuals with AF were older, mean age 64.9±8.3, and more often males, 71.4%. In Bonferroni-adjusted multivariable regression analyses strongest associations per standard deviation increase in biomarker concentrations were observed for the natriuretic peptides Nt-proBNP (odds ratio [OR] 2.89, 99.5% confidence interval [CI] 2.14–3.90; PPP<0.0001), TnI ultra (OR 1.50, 99.5% CI 1.19–1.90; P<0.0001) and. fibrinogen (OR 1.44, 99.5% CI 1.19–1.75; P13%. In conclusion, in our large, population-based study, we identified novel biomarkers reflecting vascular function, MR-proADM, inflammation, and myocardial damage, TnI ultra, as related to AF; the strong association of natriuretic peptides was confirmed. Prospective studies need to examine whether risk prediction of AF can be enhanced beyond clinical risk factors using these biomarkers.


  • Pleiotropic genes for metabolic syndrome and inflammation

    by Aldi T. Kraja, Daniel I. Chasman, Kari E. North, Alexander P. Reiner, Lisa R. Yanek, Tuomas O. Kilpeläinen, Jennifer A. Smith, Abbas Dehghan, Josée Dupuis, Andrew D. Johnson, et al.


  • Kidney injury and mortality after transcatheter aortic valve implantation in a routine clinical cohort

    by Renate B. Schnabel, Moritz Seiffert, Sandra Wilde, Johannes Schirmer, Dietmar H. Koschyk, Lenard Conradi, Francisco Ojeda, Stephan Baldus, Hermann Reichenspurner, Stefan Blankenberg, et al.

    Objectives: We aimed at identifying predictors of renal impairment and its impact on long‐term outcome after transcatheter aortic valve implantation (TAVI).Background: Renal impairment is common in mostly elderly, multimorbid patients undergoing TAVI. The risk of periprocedural renal function impairment and its association with outcome is incompletely understood.Methods: In 458 consecutive patients (mean age, 80.6 ± 7.0 years, 52.2% women) who underwent routine TAVI procedures, we assessed estimated glomerular filtration rate (eGFR) at baseline, during 72‐hr postprocedure and at discharge. Over a median follow‐up of 0.96 years, we observed 142 deaths. Results: In multivariable‐adjusted models, predictors of renal function deterioration within 72 hr were baseline eGFR (β = 0.83, 95% confidence interval [CI] = 0.76/0.91; P < 0.0001), body mass index (β = −1.20, 95% CI = 1.77/−0.62; P < 0.0001), and major access site complications (β = −14.82, 95% CI = −26.52/−3.11; P = 0.013) including bleeding (β = −11.97, 95% CI = −21.05/−2.89; P = 0.0099). Strongest renal function predictor of 1‐year mortality in risk factor adjusted analyses was the change of eGFR within 72 hr (odds ratio, 0.97; 95% CI = 0.96/0.98; P < 0.0001). The addition of information on the change of eGFR increased the C‐statistic of the logistic EuroSCORE (P = 0.021).Conclusions: In our routine TAVI sample, baseline eGFR, body mass index, and major access site complications mainly owing to bleeding were correlates of acute kidney injury after TAVI. Acute renal impairment was a risk factor for mortality and adverse cardiovascular events which provided risk information beyond the EuroSCORE.


  • Open Access

    Depression in Atrial Fibrillation in the General Population

    by Renate B. Schnabel, Matthias Michal, Sandra Wilde, Jörg Wiltink, Philipp S. Wild, Christoph R. Sinning, Edith Lubos, Francisco M. Ojeda, Tanja Zeller, Thomas Munzel, et al.

    Initial evidence suggests that depressive symptoms are more frequent in patients with atrial fibrillation. Data from the general population are limited. In 10,000 individuals (mean age 56±11 years, 49.4% women) of the population-based Gutenberg Health Study we assessed depression by the Patient Health Questionnaire (PHQ-9) and a history of depression in relation to manifest atrial fibrillation (n = 309 cases). The median (25th/75th percentile) PHQ-9 score of depressive symptoms was 4 (2/6) in atrial fibrillation individuals versus 3 (2/6) individuals without atrial fibrillation, . Multivariable regression analyses of the severity of depressive symptoms in relation to atrial fibrillation in cardiovascular risk factor adjusted models revealed a relation of PHQ-9 values and atrial fibrillation (odds ratio (OR) 1.04, 95% confidence interval (CI) 1.01–1.08; P = 0.023). The association was stronger for the somatic symptom dimension of depression (OR 1.08, 95% CI 1.02–1.15; P = 0.0085) than for cognitive symptoms (OR 1.05, 95% CI 0.98–1.11; P = 0.15). Results did not change markedly after additional adjustment for heart failure, partnership status or the inflammatory biomarker C-reactive protein. Both, self-reported physical health status, very good/good versus fair/bad, (OR 0.54, 95% CI 0.41–0.70; P<0.001) and mental health status (OR 0.61 (0.46–0.82); P = 0.0012) were associated with atrial fibrillation in multivariable-adjusted models. In a population-based sample we observed a higher burden of depressive symptoms driven by somatic symptom dimensions in individuals with atrial fibrillation. Depression was associated with a worse perception of physical or mental health status. Whether screening and treatment of depressive symptoms modulates disease progression and outcome needs to be shown.


  • Open Access

    Risk Assessment for Incident Heart Failure in Individuals With Atrial Fibrillation

    by Renate B. Schnabel, Michiel Rienstra, Lisa M. Sullivan, Jenny X. Sun, Carlee B. Moser, Daniel Levy, Michael J. Pencina, João D. Fontes, Jared W. Magnani, David D. McManus, et al.

    Background Atrial fibrillation (AF) is a strong risk factor for heart failure (HF); HF onset in patients with AF is associated with increased morbidity and mortality. Risk factors that predict HF in individuals with AF in the community are not well established. Methods and results We examined clinical variables related to the 10‐year incidence of HF in 725 individuals (mean 73.3 years, 45% women) with documented AF in the Framingham Heart Study. Event rates for incident HF (n = 161, 48% in women) were comparable in women (4.30 per 100 person‐years) and men (3.34 per 100 person‐years). Age, body mass index, ECG LV hypertrophy, diabetes, significant murmur, and history of myocardial infarction were positively associated with incident HF in multivariable models (C‐statistic 0.71; 95% confidence interval 0.67–0.75). We developed a risk algorithm for estimating absolute risk of HF in AF patients with good model fit and calibration (adjusted calibration χ2 statistic 7.29; Pχ2 = 0.61). Applying the algorithm, 47.6% of HF events occurred in the top tertile in men compared with 13.1% in the bottom tertile, and 58.4% in women in the upper tertile compared with 18.2% in the lowest category. For HF type, women had a non‐significantly higher incidence of HF with preserved EF compared with men. Conclusions We describe advancing age, LV hypertrophy, body mass index, diabetes, significant heart murmur, and history of myocardial infarction as clinical predictors of incident HF in individuals with AF. A risk algorithm may help identify individuals with AF at high risk of developing HF.


  • Multiple Inflammatory Biomarkers in Relation to Cardiovascular Events and Mortality in the Community

    by Renate B. Schnabel, Xiaoyan Yin, Martin G. Larson, Jennifer F. Yamamoto, João D. Fontes, Sekar Kathiresan, Jian Rong, Daniel Levy, Jr John F. Keaney, Thomas J. Wang, et al.

    Objective—: Evidence suggests that chronic low-grade inflammation and oxidative stress are related to cardiovascular disease (CVD) and mortality. Approach and Results—: We examined 11 established and novel biomarkers representing inflammation and oxidative stress (C-reactive protein, fibrinogen, interleukin-6, intercellular adhesion molecule-1, lipoprotein-associated phospholipase-A2 [mass and activity], monocyte chemoattractant protein-1, myeloperoxidase, CD40 ligand, P-selectin, and tumor necrosis factor receptor II [TNFRII]) in relation to incident major CVD and mortality in the community. We studied 3035 participants (mean age, 61±9 years; 53% women). During follow-up (median, 8.9 years), 253 participants experienced a CVD event and 343 died. C-reactive protein (hazard ratio [HR] reported per SD ln-transformed biomarker, 1.18; 95% confidence interval [CI], 1.02–1.35; nominal P =0.02) and TNFRII (HR, 1.15; 95% CI, 1.01–1.32; nominal P =0.04) were retained in multivariable-adjusted models for major CVD, but were not significant after adjustment for multiple testing. The biomarkers related to mortality were TNFRII (HR, 1.33; 95% CI, 1.19–1.49; P P P P <0.0001), but not for CVD. Conclusions—: Of 11 inflammatory biomarkers tumor necrosis factor receptor II was related to cardiovascular disease and mortality in the Framingham Heart Study. The combination of TNFRII with C-reactive protein in relation to CVD and with interleukin-6 to mortality increased the predictive ability in addition to CVD risk factors for total mortality but not for incident CVD.


  • Sex differences in noninvasive vascular function in the community

    by Renate B. Schnabel, Moritz P. Biener, Sandra Wilde, Christoph R. Sinning, Francisco M. Ojeda, Tanja Zeller, Edith Lubos, Karl J. Lackner, Ascan Warnholtz, Tommaso Gori, et al.

    Objective: The relation of noninvasive vascular function to sex, sex hormones, and reproductive history in the general population is little understood. Methods: We simultaneously assessed flow-mediated dilation (FMD) and peripheral arterial tonometry in 454 women (mean age 40.4 ± 16.1 years, age range 19–78 years) and 100 men (mean age 44.7 ± 15.3 years) in a community-based cohort. Plasma estradiol, progesterone, luteinizing hormone, and follicle stimulating hormones were measured, and menstrual cycle and reproductive history were recorded. Results: Vascular function was blunted in men as compared to women irrespective of menopausal status and adjustment for classical cardiovascular risk factors and hormones. Vascular reactivity changed during the menstrual cycle and correlated with estradiol concentrations for FMD, r = 0.13 and inversely with progesterone for pulse amplitude, r = −0.14, and brachial artery diameter, r = −0.10. Multivariable-adjusted regressions showed a relation of estradiol with FMD, β 0.658, 95% confidence interval (CI) 0.084/1.232, P = 0.025 in women. Age at menarche (β 0.070, 95% CI 0.039/0.101, P < 0.0001) and breastfeeding duration (β −0.006, 95% CI −0.011/−0.001, P = 0.036) were related to brachial artery diameter, age at menarche also to FMD (β −0.455, 95% CI −0.886/−0.023, P = 0.039). Conclusion: Sex differences in noninvasive conduit and peripheral arterial function with better vascular reactivity in women were not fully explained by female sex hormones and menopausal status. Age at menarche and duration of breastfeeding were also related to vascular function and need further investigation.


  • Open Access

    Association of soluble endothelial protein C receptor plasma levels and PROCR rs867186 with cardiovascular risk factors and cardiovascular events in coronary artery disease patients: The Athero Gene Study

    by Choumous Kallel, William Cohen, Noémie Saut, Stefan Blankenberg, Renate Schnabel, Hans J Rupprecht, Christoph Bickel, Thomas Munzel, David-Alexandre Tregouet, Pierre-Emmanuel Morange

    Background: Blood coagulation is an essential determinant of coronary artery disease (CAD). Soluble Endothelial Protein C Receptor (sEPCR) may be a biomarker of a hypercoagulable state. We prospectively investigated the relationship between plasma sEPCR levels and the risk of cardiovascular events (CVE). Methods: We measured baseline sEPCR levels in 1673 individuals with CAD (521 with acute coronary syndrome [ACS] and 1152 with stable angina pectoris [SAP]) from the AtheroGene cohort. During a median follow up of 3.7 years, 136 individuals had a CVE. In addition, 891 of these CAD patients were genotyped for the PROCR rs867186 (Ser219Gly) variant. Results: At baseline, sEPCR levels were similar in individuals with ACS and SAP (median: 111 vs. 115 ng/mL respectively; p=0.20). Increased sEPCR levels were found to be associated with several cardiovascular risk factors including gender (p=0.006), soluble Tissue Factor levels (p=0.0001), diabetes (p=0.0005), and factors reflecting impaired renal function such as creatinine and cystatin C (p-200) but did not associate with CVE risk. Conclusion: Our findings show that in patients with CAD, circulating sEPCR levels are related to classical cardiovascular risk factors and renal impairment but are not related to long-term incidence of CVE.